Washington Post examines development of vaccine for food borne intestinal illness

NewsGuard 100/100 Score

The Partnership for Public Service/Washington Post examines how decades of work by Navy scientist Patricia Guerry could lead to "the first vaccine for a food borne intestinal illness that affects hundreds of millions of people worldwide each year."

"The vaccine candidate against the pathogen Campylobacter jejuni, developed by Guerry, her colleagues at the U.S. Naval Medical Research Center in Silver Spring and Canadian scientist Mario Monteiro, successfully protected against infection in monkeys during testing last year and is slated for human clinical trials," the newspaper writes.

According to the Washington Post, an "effective vaccine … could potentially save tens of thousands of young lives in developing countries where the pathogen has proved deadly," the newspaper writes. The article includes additional information about how the vaccine was developed (8/24).

http://kaisernetwork.org 


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses